Molecular Formula | C30H40N6O10 |
Molar Mass | 644.67 |
Density | 1.291±0.06 g/cm3(Predicted) |
Boling Point | 896.0±65.0 °C(Predicted) |
Solubility | ( < 1 mg/ml refers to the product slightly soluble or insoluble) |
pKa | 11.25±0.46(Predicted) |
Storage Condition | -20℃ |
Use | Boc-Val-Cit-PAB-PNP is a degradable (cleavable) ADC linker that can be used to synthesize antibody-coupled drugs (ADC). |
Target | Cleavable |
In vitro study | ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker. |
In vivo study | The ADC is composed of an antibody, and the ADC cytotoxin is bound to the antibody via the ADC linker. |
Reference Show more | 1. Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017 May;16(5):315-337. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 1.551 ml | 7.756 ml | 15.512 ml |
5 mM | 0.31 ml | 1.551 ml | 3.102 ml |
10 mM | 0.155 ml | 0.776 ml | 1.551 ml |
5 mM | 0.031 ml | 0.155 ml | 0.31 ml |
use | Boc-Val-Cit-PAB-PNP is a cleavable (cleavable) ADC linker that can be used to synthesize antibody-coupled drugs (ADC). |
in vivo study | ADC consists of antibodies, which bind ADC cytotoxins to antibodies through ADC connectors. |
biological activity | Boc-Val-Cit-PAB-PNP is a cleavable ADC linker for the synthesis of antibody-coupled drugs (ADCs). |
target | Cleavable |
in vitro study | ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker.